{"transactions":[{"id":712987,"issuer":{"id":7572,"kind":"organization","name":"Cellectar Biosciences, Inc."},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-07-09T01:10:28.000Z","date":"2026-07-07","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":25000,"derivative":{"exercise_price":2.7,"expiration_date":"2036-07-07","underlying":"Common stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-26-082016","document":"tm2620095-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000110465926082016/tm2620095-8_4seq1.xml","form_type":"4"}},{"id":996297,"issuer":{"id":7396,"kind":"organization","name":"Lite Strategy, Inc."},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-18T23:36:40.000Z","date":"2025-11-14","kind":"grant","planned":false,"acquired":true,"shares":55000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received as compensation for service on the Board."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Customary annual grant to non-employee directors of options to purchase shares of common stock. Such options shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning December 14, 2025 and continuing on the first day of each calendar month following such date and continuing through November 14, 2026."}],"balance_after":55000,"derivative":{"exercise_price":2.02,"expiration_date":"2035-11-14","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001193125-25-286568","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000119312525286568/ownership.xml","form_type":"4"}},{"id":1085812,"issuer":{"id":7396,"kind":"organization","name":"Lite Strategy, Inc."},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-18T01:33:57.000Z","date":"2025-07-15","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Customary annual grant to non-employee directors of options to purchase shares of common stock was not made during the fiscal year ended June 30, 2025."}],"balance_after":20000,"derivative":{"exercise_price":3.07,"exercise_date":"2025-07-15","expiration_date":"2035-07-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000929638-25-002634","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000092963825002634/form4.xml","form_type":"4"}},{"id":1264564,"issuer":{"id":7572,"kind":"organization","name":"Cellectar Biosciences, Inc."},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-02-18T21:03:34.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full on February 14, 2026, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":60000,"derivative":{"exercise_price":0.29,"expiration_date":"2035-02-14","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001104659-25-014740","document":"tm256830-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000110465925014740/tm256830-3_4seq1.xml","form_type":"4"}},{"id":1315854,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-03T21:00:12.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":24400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 2, 2025. The option is scheduled to vest as to 50% of the underlying shares on the six-month anniversary of the grant date and as to the remaining 50% on the first anniversary of the grant date."}],"balance_after":24400,"derivative":{"exercise_price":1.09,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":24400},"source":{"system":"sec-edgar","filing":"0000950170-25-001106","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000095017025001106/ownership.xml","form_type":"4"}},{"id":1475924,"issuer":{"id":7572,"kind":"organization","name":"Cellectar Biosciences, Inc."},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2024-06-18T21:00:33.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This option was contingently granted on December 22, 2023, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2024 Annual Meeting of Stockholders. Such stockholder approval was obtained on June 14, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest in full on December 22, 2024, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":60000,"derivative":{"exercise_price":2.58,"expiration_date":"2033-12-22","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001104659-24-072880","document":"tm2417520-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000110465924072880/tm2417520-2_4seq1.xml","form_type":"4"}},{"id":1688605,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-01-04T21:02:02.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":24400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 2, 2024. The shares underlying the option are scheduled to vest in full on the anniversary date of the grant date."}],"balance_after":24400,"derivative":{"exercise_price":2.78,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":24400},"source":{"system":"sec-edgar","filing":"0000950170-24-001829","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000095017024001829/ownership.xml","form_type":"4"}},{"id":1761260,"issuer":{"id":7396,"kind":"organization","name":"Lite Strategy, Inc."},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-12T23:41:59.000Z","date":"2023-09-29","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning October 1, 2023 and continuing on the first day of each calendar month following such date and continuing through July 1, 2024."}],"balance_after":10000,"derivative":{"exercise_price":7.01,"expiration_date":"2033-09-29","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000929638-23-002773","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000092963823002773/form4.xml","form_type":"4"}},{"id":1842895,"issuer":{"id":7572,"kind":"organization","name":"Cellectar Biosciences, Inc."},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-06-28T22:24:30.000Z","date":"2023-06-28","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option shall vest in full on June 28, 2024, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":47650,"derivative":{"exercise_price":1.85,"expiration_date":"2033-06-28","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-23-075938","document":"tm2320030-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000110465923075938/tm2320030-2_4seq1.xml","form_type":"4"}},{"id":2063300,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-01-05T21:08:07.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 3, 2023.  The shares underlying the option are scheduled to vest in full on the anniversary date of the grant date."}],"balance_after":10000,"derivative":{"exercise_price":2.66,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-23-001776","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919123001776/doc4.xml","form_type":"4"}},{"id":2199239,"issuer":{"id":7572,"kind":"organization","name":"Cellectar Biosciences, Inc."},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2022-08-01T22:00:54.000Z","date":"2022-06-24","kind":"grant","acquired":true,"shares":7800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Exercise price and quantity have been adjusted for the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022."},{"field":"shares","element":"transactionShares","label":"F1","text":"Exercise price and quantity have been adjusted for the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option shall vest in full on June 24, 2023, subject to the reporting person's continued service through the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Exercise price and quantity have been adjusted for the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Exercise price and quantity have been adjusted for the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022."}],"balance_after":7800,"derivative":{"exercise_price":4.1,"expiration_date":"2032-06-24","underlying":"Common Stock","underlying_shares":7800},"source":{"system":"sec-edgar","filing":"0001104659-22-084835","document":"tm2222253-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000110465922084835/tm2222253-2_4seq1.xml","form_type":"4"}},{"id":2210913,"issuer":{"id":7396,"kind":"organization","name":"Lite Strategy, Inc."},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-07T20:27:15.000Z","date":"2022-07-05","kind":"grant","acquired":true,"shares":87.5,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in equal monthly installments over twelve months."}],"balance_after":87500,"derivative":{"exercise_price":0.54,"expiration_date":"2032-07-05","underlying":"Common Stock","underlying_shares":87500},"source":{"system":"sec-edgar","filing":"0000899243-22-025712","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000089924322025712/doc4.xml","form_type":"4"}},{"id":2316861,"issuer":{"id":114644,"kind":"organization","name":"Renovacor, Inc.","symbol":"RCOR"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option","published_at":"2022-03-28T23:38:10.000Z","date":"2022-03-28","kind":"grant","acquired":true,"shares":155325,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest and become exercisable in full on March 28, 2026, with 25% vesting on March 28, 2023, and the remainder vesting in equal monthly installments for the remaining 36 months, subject to the continuous service of the Reporting Person on such vesting date."}],"balance_after":155325,"derivative":{"exercise_price":4.3,"expiration_date":"2032-03-28","underlying":"Common Stock","underlying_shares":155325},"source":{"system":"sec-edgar","filing":"0001062993-22-008797","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000106299322008797/form4.xml","form_type":"4"}},{"id":2444879,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-06T01:22:05.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 3, 2022.  The shares underlying the option are scheduled to vest in full on the anniversary of the grant date."}],"balance_after":10000,"derivative":{"exercise_price":12.28,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-22-001046","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000089924322001046/doc4.xml","form_type":"4"}},{"id":2503331,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-11-19T15:00:04.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":168000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Merger, each outstanding option with an exercise price less than $8.50 per share was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive (i) cash in an amount equal to the product of (a) the total number of shares of Issuer common stock subject to such option multiplied by (b) the excess of (x) $8.50 per share over (y) the exercise price payable per share of Issuer common stock under such option, and (ii) any potential CVR Payments, net of any withholding taxes required to be deducted and withheld by applicable legal requirements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the effective time of the Merger, each outstanding option with an exercise price less than $8.50 per share was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive (i) cash in an amount equal to the product of (a) the total number of shares of Issuer common stock subject to such option multiplied by (b) the excess of (x) $8.50 per share over (y) the exercise price payable per share of Issuer common stock under such option, and (ii) any potential CVR Payments, net of any withholding taxes required to be deducted and withheld by applicable legal requirements."}],"balance_after":0,"derivative":{"exercise_price":8.35,"expiration_date":"2031-05-31","underlying":"Common Stock","underlying_shares":168000},"source":{"system":"sec-edgar","filing":"0001209191-21-065705","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919121065705/doc4.xml","form_type":"4"}},{"id":2503330,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-19T15:00:04.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":30680,"price":8.5,"value":260780.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. (\"Issuer\"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. (\"Purchaser\") (\"Merger Agreement\"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation (\"Merger\"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash (\"Cash Amount\"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 (\"CVR Payments\"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments."},{"field":"shares","element":"transactionShares","label":"F2","text":"At the effective time of the Merger, each outstanding restricted stock unit award (\"RSU\") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-065705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919121065705/doc4.xml","form_type":"4"}},{"id":2577560,"issuer":{"id":7572,"kind":"organization","name":"Cellectar Biosciences, Inc."},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-07T20:01:41.000Z","date":"2021-09-03","kind":"purchase","acquired":true,"shares":19417,"price":1.0426,"value":20244.1642,"ownership":{"direct":true},"balance_after":19417,"source":{"system":"sec-edgar","filing":"0001104659-21-113416","document":"tm2127071-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000110465921113416/tm2127071-1_4seq1.xml","form_type":"4"}},{"id":2641737,"issuer":{"id":7396,"kind":"organization","name":"Lite Strategy, Inc."},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-06T22:58:07.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in equal monthly installments over twelve months."}],"balance_after":50000,"derivative":{"exercise_price":2.95,"expiration_date":"2031-07-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-21-045655","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919121045655/doc4.xml","form_type":"4"}},{"id":2645447,"issuer":{"id":7572,"kind":"organization","name":"Cellectar Biosciences, Inc."},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-07-02T20:03:06.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":78000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest on the first anniversary of the date of grant."}],"balance_after":78000,"derivative":{"exercise_price":1.19,"expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":78000},"source":{"system":"sec-edgar","filing":"0001104659-21-088836","document":"tm2120855-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000110465921088836/tm2120855-3_4seq1.xml","form_type":"4"}},{"id":2684016,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-06-03T20:20:29.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":168000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option shall vest on the one-year anniversary of May 17, 2021 (the \"Vesting Commencement Date\"), and 1/48th of the shares subject to the option shall vest each month following the one-year anniversary of the Vesting Commencement Date, so that all of the shares subject to the options shall be vested four years after the Vesting Commencement Date."}],"balance_after":168000,"derivative":{"exercise_price":8.35,"expiration_date":"2031-05-31","underlying":"Common Stock","underlying_shares":168000},"source":{"system":"sec-edgar","filing":"0001209191-21-037641","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919121037641/doc4.xml","form_type":"4"}},{"id":2684015,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-03T20:20:29.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan."}],"balance_after":30680,"source":{"system":"sec-edgar","filing":"0001209191-21-037641","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919121037641/doc4.xml","form_type":"4"}},{"id":2836289,"issuer":{"id":7396,"kind":"organization","name":"Lite Strategy, Inc."},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-24T17:08:04.000Z","date":"2021-02-23","kind":"sale","acquired":false,"shares":25000,"price":4.025,"value":100625.0,"ownership":{"direct":true},"balance_after":37500,"source":{"system":"sec-edgar","filing":"0001209191-21-013670","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919121013670/doc4.xml","form_type":"4"}},{"id":2916318,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-01-06T21:44:01.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 4, 2021. The shares underlying the option are scheduled to vest in full on the anniversary of the grant date."}],"balance_after":10000,"derivative":{"exercise_price":12.36,"expiration_date":"2031-01-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-21-000710","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000089924321000710/doc4.xml","form_type":"4"}},{"id":3058924,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-13T20:31:30.000Z","date":"2020-08-11","kind":"sale","acquired":false,"shares":5300,"price":10.7669,"value":57064.57,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales made in order to satisfy tax payments paid, accrued and/or owed by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average share price of an aggregate total of 5,300 shares sold in the price range of $10.50 to $11.07 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":109235,"source":{"system":"sec-edgar","filing":"0001209191-20-046606","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919120046606/doc4.xml","form_type":"4"}},{"id":3058923,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-13T20:31:30.000Z","date":"2020-08-11","kind":"sale","acquired":false,"shares":10000,"price":9.9787,"value":99787.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales made in order to satisfy tax payments paid, accrued and/or owed by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average share price of an aggregate total of 10,000 shares sold in the price range of $9.94 to $10.0301 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":114535,"source":{"system":"sec-edgar","filing":"0001209191-20-046606","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919120046606/doc4.xml","form_type":"4"}},{"id":3058922,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-13T20:31:30.000Z","date":"2020-08-11","kind":"sale","acquired":false,"shares":50000,"price":10.224,"value":511200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales made in order to satisfy tax payments paid, accrued and/or owed by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 50,000 shares sold in the price range of $9.89 to $10.7275 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":124535,"source":{"system":"sec-edgar","filing":"0001209191-20-046606","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919120046606/doc4.xml","form_type":"4"}},{"id":3087680,"issuer":{"id":7396,"kind":"organization","name":"Lite Strategy, Inc."},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-07T17:15:43.000Z","date":"2020-07-02","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in equal monthly installments over twelve months."}],"balance_after":50000,"derivative":{"exercise_price":3.49,"expiration_date":"2030-07-02","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-20-018615","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000089924320018615/doc4.xml","form_type":"4"}},{"id":3100075,"issuer":{"id":7572,"kind":"organization","name":"Cellectar Biosciences, Inc."},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2020-06-25T20:21:50.000Z","date":"2020-06-24","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant shall vest over a period of three years from the grant date, with one-third vesting on  the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a  24 month period beginning on the first anniversary of the grant date."}],"balance_after":50000,"derivative":{"exercise_price":1.28,"expiration_date":"2030-06-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-20-076870","document":"tm2023456d2_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000110465920076870/tm2023456d2_4.xml","form_type":"4"}},{"id":3113677,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-11T22:22:07.000Z","date":"2020-06-10","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 10, 2021 or the date immediately preceding the 2021 annual meeting of stockholders."}],"balance_after":100000,"derivative":{"exercise_price":6.21,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-20-036034","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919120036034/doc4.xml","form_type":"4"}},{"id":3318926,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-01-06T22:52:43.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted on January 2, 2020 pursuant to the Issuer's Director Compensation Policy."}],"balance_after":8000,"derivative":{"exercise_price":16.31,"exercise_date":"2021-01-02","expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-20-002057","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919120002057/doc4.xml","form_type":"4"}},{"id":3334081,"issuer":{"id":7396,"kind":"organization","name":"Lite Strategy, Inc."},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-20T17:56:30.000Z","date":"2019-12-19","kind":"purchase","acquired":true,"shares":62500,"price":1.6,"value":100000.0,"ownership":{"direct":true},"balance_after":62500,"source":{"system":"sec-edgar","filing":"0001209191-19-061473","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919119061473/doc4.xml","form_type":"4"}},{"id":3468687,"issuer":{"id":7396,"kind":"organization","name":"Lite Strategy, Inc."},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-03T19:32:11.000Z","date":"2019-07-01","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in equal monthly installments over twelve months."}],"balance_after":40000,"derivative":{"exercise_price":2.52,"expiration_date":"2029-07-01","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-19-040977","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919119040977/doc4.xml","form_type":"4"}},{"id":3489896,"issuer":{"id":7572,"kind":"organization","name":"Cellectar Biosciences, Inc."},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2019-06-14T20:32:00.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest on the one year anniversary of the date of grant."}],"balance_after":6500,"derivative":{"exercise_price":2.15,"expiration_date":"2029-06-13","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001144204-19-031009","document":"tv523610_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000114420419031009/tv523610_4.xml","form_type":"4"}},{"id":3497452,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-07T20:41:14.000Z","date":"2019-06-06","kind":"grant","acquired":true,"shares":92592,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of NantKwest, Inc. common stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of June 6, 2020 or the date immediately preceding the 2020 annual meeting of stockholders."}],"balance_after":174535,"source":{"system":"sec-edgar","filing":"0001209191-19-035583","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919119035583/doc4.xml","form_type":"4"}},{"id":3709610,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-01-03T23:36:50.000Z","date":"2019-01-02","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8000,"derivative":{"exercise_price":5.16,"exercise_date":"2020-01-02","expiration_date":"2026-01-02","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-19-001324","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919119001324/doc4.xml","form_type":"4"}},{"id":3791181,"issuer":{"id":7572,"kind":"organization","name":"Cellectar Biosciences, Inc."},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2018-10-15T23:49:59.000Z","date":"2018-10-12","kind":"grant","acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant was divided into a definitive grant of 6,150 shares, which vest in equal monthly installments over a seven month period from the grant date, and a contingent grant of 6,850 shares, which are subject to the following conditions: (i) approval by Cellectar's stockholders of an increase in shares available under the Amended and Restated 2015 Stock Incentive Plan at the Corporation's 2019 annual meeting of stockholders or other special meeting of stockholders called for such purpose; and (ii) to the extent stockholder approval is received, the contingent grant shall vest immediately upon such stockholder approval."}],"balance_after":13000,"derivative":{"exercise_price":2.61,"expiration_date":"2028-10-12","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001144204-18-053879","document":"tv504844_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000114420418053879/tv504844_form4.xml","form_type":"4"}},{"id":3867434,"issuer":{"id":7396,"kind":"organization","name":"Lite Strategy, Inc."},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-07-16T21:26:40.000Z","date":"2018-07-12","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in equal monthly installments over twelve months."}],"balance_after":40000,"derivative":{"exercise_price":4.28,"expiration_date":"2028-07-12","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-18-042667","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919118042667/doc4.xml","form_type":"4"}},{"id":3882475,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-27T20:17:59.000Z","date":"2018-06-26","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These Stock Options become exercisable in eight equal semi-annual installments beginning December 26, 2018."}],"balance_after":50000,"derivative":{"exercise_price":12.97,"expiration_date":"2025-06-26","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-18-039658","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919118039658/doc4.xml","form_type":"4"}},{"id":3898657,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-11T20:16:20.000Z","date":"2018-06-07","kind":"grant","acquired":true,"shares":27322,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of NantKwest, Inc. common stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of June 7, 2019 or the date immediately preceding the 2019 annual meeting of stockholders."}],"balance_after":81943,"source":{"system":"sec-edgar","filing":"0001209191-18-036923","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919118036923/doc4.xml","form_type":"4"}},{"id":4034451,"issuer":{"id":7396,"kind":"organization","name":"Lite Strategy, Inc."},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options to purchase shares of common stock","published_at":"2018-02-26T18:12:56.000Z","date":"2018-02-22","kind":"grant","acquired":true,"shares":33333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"20,000 options will vest ratably each month beginning March 1, 2018 over thirty-six months, and 13,333 of the options will vest ratably each month beginning March 1, 2018 over four months."}],"balance_after":33333,"derivative":{"exercise_price":2.19,"expiration_date":"2028-02-22","underlying":"Common Stock, par value $0.00000002 per share","underlying_shares":33333},"source":{"system":"sec-edgar","filing":"0001209191-18-013268","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919118013268/doc4.xml","form_type":"4"}},{"id":4204978,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-20T21:35:24.000Z","date":"2017-09-18","kind":"grant","acquired":true,"shares":54621,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of NantKwest, Inc. common stock. Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, one thirty-sixth (1/36th) of the RSUs subject to the award will vest monthly over thirty six (36) months, such that the award will be fully vested on September 18, 2020."}],"balance_after":54621,"source":{"system":"sec-edgar","filing":"0001209191-17-053488","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919117053488/doc4.xml","form_type":"4"}},{"id":4298305,"issuer":{"id":7572,"kind":"organization","name":"Cellectar Biosciences, Inc."},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2017-06-01T22:04:00.000Z","date":"2017-05-31","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest in equal annual increments over a period of three years from the date of grant."}],"balance_after":10000,"derivative":{"exercise_price":1.74,"expiration_date":"2027-05-31","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001144204-17-030682","document":"v468271_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000114420417030682/v468271_4.xml","form_type":"4"}},{"id":4372746,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2017-03-24T20:24:10.000Z","date":"2017-03-23","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4 of the shares subject to the option vest one year after May 20, 2013, with 1/48th of the shares vesting monthly thereafter over the next 3 years."}],"balance_after":102300,"derivative":{"exercise_price":7.8861,"expiration_date":"2023-05-19","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-17-022762","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919117022762/doc4.xml","form_type":"4"}},{"id":4372745,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-03-24T20:24:10.000Z","date":"2017-03-23","kind":"sale","acquired":false,"shares":3000,"price":23,"value":69000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted December 20, 2016."}],"balance_after":7777,"source":{"system":"sec-edgar","filing":"0001209191-17-022762","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919117022762/doc4.xml","form_type":"4"}},{"id":4372744,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-03-24T20:24:10.000Z","date":"2017-03-23","kind":"exercise","acquired":true,"shares":3000,"price":7.8861,"value":23658.3,"ownership":{"direct":true},"balance_after":10777,"source":{"system":"sec-edgar","filing":"0001209191-17-022762","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919117022762/doc4.xml","form_type":"4"}},{"id":4410157,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2017-03-02T21:56:09.000Z","date":"2017-02-28","kind":"exercise","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/4 of the shares subject to the option vest one year after May 20, 2013, with 1/48th of the shares vesting monthly thereafter over the next 3 years."}],"balance_after":105300,"derivative":{"exercise_price":7.8861,"expiration_date":"2023-05-19","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-17-016741","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919117016741/doc4.xml","form_type":"4"}},{"id":4410156,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-03-02T21:56:09.000Z","date":"2017-02-28","kind":"sale","acquired":false,"shares":600,"price":20.4167,"value":12250.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted December 20, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $20.4167, and the range of prices were between $20.41 and $20.43.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":7777,"source":{"system":"sec-edgar","filing":"0001209191-17-016741","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919117016741/doc4.xml","form_type":"4"}},{"id":4410155,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-03-02T21:56:09.000Z","date":"2017-02-28","kind":"sale","acquired":false,"shares":32834,"price":19.9619,"value":655429.0246,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted December 20, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $19.9619, and the range of prices were between $19.41 and $20.40.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":8377,"source":{"system":"sec-edgar","filing":"0001209191-17-016741","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919117016741/doc4.xml","form_type":"4"}},{"id":4410154,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-03-02T21:56:09.000Z","date":"2017-02-28","kind":"exercise","acquired":true,"shares":30000,"price":7.8861,"value":236583.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 680 shares of Common Stock that were acquired by the Reporting Person on November 20, 2015 pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":41211,"source":{"system":"sec-edgar","filing":"0001209191-17-016741","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919117016741/doc4.xml","form_type":"4"}},{"id":4511931,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2016-12-27T22:00:30.000Z","date":"2016-12-20","kind":"other","acquired":true,"shares":1134,"price":9.01,"value":10217.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 is being filed voluntarily to report the acquisition of 1,134 shares by the Reporting Person on December 20, 2016 pursuant to the Issuer's Employee Stock Purchase Plan."},{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 is being filed voluntarily to report the acquisition of 1,134 shares by the Reporting Person on December 20, 2016 pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":10531,"source":{"system":"sec-edgar","filing":"0001209191-16-156828","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919116156828/doc4.xml","form_type":"4"}},{"id":4513431,"issuer":{"id":16545,"kind":"organization","name":"Flexion Therapeutics Inc","symbol":"FLXN"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2016-12-22T21:38:05.000Z","date":"2016-12-20","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option shall vest one year after December 20, 2016; thereafter one-forty-eighth (1/48th) of the shares subject to the option shall vest each month following the one year anniversary of December 20, 2016, so that all of the shares subject to the option shall be vested four (4) years after December 20, 2016."}],"balance_after":50000,"derivative":{"exercise_price":18.56,"expiration_date":"2026-12-19","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-16-156531","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000120919116156531/doc4.xml","form_type":"4"}}]}